Avian Colibacillosis: Diagnosis, Antimicrobial Resistance Trends, and Control Strategies in Poultry Flocks

Abstract

Avian colibacillosis represents one of the most economically significant bacterial diseases affecting commercial poultry operations worldwide. The condition arises from infection with extra-intestinal pathogenic Escherichia coli (ExPEC), specifically avian pathogenic Escherichia coli (APEC), which possesses a distinct repertoire of virulence factors enabling systemic colonization. This review synthesizes current knowledge regarding the pathogenesis, diagnostic algorithms, antimicrobial resistance (AMR) epidemiology, and integrated control strategies for colibacillosis in poultry flocks. Particular emphasis is placed on molecular diagnostic advances, genomic characterization of resistant lineages including Escherichia coli ST131, and the role of autogenous vaccines in mitigation programs.

1. Introduction

Colibacillosis manifests as a spectrum of clinical syndromes including airsacculitis, pericarditis, perihepatitis, septicemia, and cellulitis. The disease typically occurs as a secondary complication following viral respiratory insults or environmental stressors that compromise mucosal barriers. Economic losses stem from increased mortality, condemnation at processing, reduced feed conversion efficiency, and antimicrobial treatment costs. The emergence of extensively drug-resistant (XDR) APEC strains harboring carbapenemase genes such as OXA-244 has elevated the urgency for sustainable control measures [1]. Genomic surveillance of APEC populations reveals high plasticity driven by horizontal gene transfer, plasmid acquisition, and phage-mediated transduction [2].

2. Etiology and Pathogenesis

2.1 Bacterial Classification and Virulence Architecture

APEC belongs to the ExPEC pathotype and shares genetic similarities with human uropathogenic E. coli (UPEC) and neonatal meningitis E. coli (NMEC). The APEC pan-genome comprises a conserved core genome and a flexible accessory genome encoding virulence determinants. Key virulence factors include:

• Adhesins: Fimbrial (F1, P, S, type 1) and non-fimbrial (TibA, AIDA-I) structures mediating attachment to respiratory and intestinal epithelium
• Iron acquisition systems: Aerobactin, salmochelin, yersiniabactin, and sitABCD operon
• Capsular polysaccharides: K1, K5, and other serogroups conferring serum resistance
• Toxins: Cytotoxic necrotizing factor 1 (CNF1), hemolysin (HlyA), and secreted autotransporter toxins (Sat, Vat)
• Biofilm formation: Curli fimbriae, cellulose, and poly-N-acetylglucosamine (PNAG)

The ecnAB toxin-antitoxin system has been demonstrated to modulate APEC virulence through regulation of the capsular sialic acid biosynthesis pathway, representing a novel post-transcriptional control mechanism linking metabolic stress to virulence expression [3].

2.2 Host-Pathogen Interactions

Following inhalation or ingestion, APEC encounters the mucosal immune system. The bacterium employs type VI secretion systems (T6SS) to deliver effector proteins into host cells, subverting phagocytosis and inflammasome activation. Complement resistance is mediated by the outer membrane protease T (OmpT) and the increased serum survival (Iss) protein. Systemic dissemination occurs via macrophage trafficking or direct vascular invasion, leading to fibrinous polyserositis characteristic of acute septicemic colibacillosis.

3. Clinical Presentation and Necropsy Findings

3.1 Clinical Signs

Clinical manifestations vary by age, immune status, and concurrent infections:

3.2 Gross Pathology

Necropsy findings are diagnostic in typical cases:

• Fibrinous polyserositis: Fibrin deposits on pericardium, liver capsule, air sacs, and peritoneal surfaces
• Airsacculitis: Thickened, opaque air sacs with caseous exudate
• Pericarditis: "Bread and butter" appearance with fibrin strands
• Perihepatitis: Fibrinous coating of liver capsule (Glisson's capsule)
• Splenomegaly: Enlarged, congested spleen with white foci
• Bone lesions: Osteomyelitis and synovitis in chronic cases

4. Diagnostic Approaches

4.1 Conventional Culture and Identification

Isolation remains the gold standard for definitive diagnosis. Samples include heart blood, liver, spleen, air sac swabs, and bone marrow. Culture on MacConkey agar yields lactose-fermenting pink colonies. Biochemical confirmation utilizes indole production, methyl red positivity, Voges-Proskauer negativity, and citrate utilization (IMViC profile). Commercial automated impedance analyzers and chromogenic media accelerate identification.

4.2 Molecular Diagnostics

4.2.1 Polymerase Chain Reaction Assays

Multiplex PCR targeting virulence-associated genes (VAGs) enables pathotype differentiation. Minimum VAG panels include:

• iss (increased serum survival)
• iutA (aerobactin receptor)
• hlyF (hemolysin)
• iroN (salmochelin receptor)
• ompT (outer membrane protease)
• cvaC (colicin V production)

A VAG score ≥4 correlates with high pathogenic potential. Quantitative PCR (qPCR) provides bacterial load estimation, correlating with lesion severity.

4.2.2 Whole Genome Sequencing

High-throughput sequencers generate complete genomes for phylogenetic analysis, resistome profiling, and virulence gene repertoire characterization. Core genome multilocus sequence typing (cgMLST) and single nucleotide polymorphism (SNP) analysis resolve outbreak clusters. Recent sequencing of 21 APEC isolates from Georgia poultry revealed diverse sequence types (ST117, ST140, ST295, ST354, ST429, ST617) with variable plasmid content [2].

4.2.3 Serotyping and Phylogrouping

O:H serotyping remains epidemiologically valuable. Predominant APEC serogroups include O1, O2, O18, O78, and O111. Phylogenetic grouping (A, B1, B2, D, E, F) via Clermont typing or whole genome analysis shows APEC predominantly in phylogroups B2 and D, overlapping with human ExPEC lineages including ST131.

4.3 Differential Diagnosis

Colibacillosis must be differentiated from:

• Mycoplasma gallisepticum infection: Chronic respiratory disease with mucoid exudate; rapid visual detection via recombinase-aided amplification with lateral-flow dipstick assay facilitates field diagnosis [4]
• Avian influenza: High mortality, hemorrhagic lesions; molecular subtyping required
• Newcastle disease: Neurological signs, hemorrhagic proventriculitis
• Ornithobacterium rhinotracheale: Similar airsacculitis; requires specific culture conditions
• Fowl cholera (Pasteurella multocida): Bipolar staining organisms, different antibiotic susceptibility

4.4 Diagnostic Decision Tree

flowchart TD
    A[Clinical Suspicion: Respiratory Signs, Mortality, Fibrinous Lesions], > B{Necropsy Findings}
    B, >|Fibrinous Polyserositis| C[Sample Collection: Heart Blood, Liver, Air Sacs]
    B, >|Mucoid Exudate, No Fibrin| D[Consider Mycoplasma gallisepticum]
    B, >|Hemorrhagic Lesions| E[Rule Out AI, ND, Fowl Cholera]
    C, > F[Primary Culture: MacConkey, Blood Agar]
    F, > G[Biochemical Confirmation: IMViC, Automated ID]
    G, > H{Molecular Characterization}
    H, >|VAG PCR Panel| I[Pathotype Classification: APEC vs Commensal]
    H, >|WGS| J[ST Determination, Resistome, Virulome, Plasmidome]
    H, >|Serotyping| K[O:H Serogroup Assignment]
    I, > L[Antimicrobial Susceptibility Testing: Broth Microdilution]
    J, > L
    K, > L
    L, > M[AMR Profile: ESBL, AmpC, Carbapenemase Screening]
    M, > N[Treatment Selection / Autogenous Vaccine Strain Selection]
    D, > O[Mg-Specific PCR / RAA-LFD Assay]
    E, > P[Pathogen-Specific RT-PCR Panels]

5. Antimicrobial Resistance Trends

5.1 Global Resistance Patterns

APEC isolates exhibit high resistance frequencies to critically important antimicrobials. Surveillance data indicate:

5.2 Emerging Resistance Threats

5.2.1 Carbapenemase-Producing APEC

Detection of OXA-244 carbapenemase-producing E. coli in farm animals represents a critical One Health concern [1]. OXA-244 confers reduced susceptibility to carbapenems, the last-resort agents for human multidrug-resistant Gram-negative infections. The gene is typically located on IncX3 or IncF plasmids co-harboring ESBL genes.

5.2.2 Extensively Drug-Resistant Lineages

Genomic characterization of an XDR APEC strain revealed accumulation of resistance determinants on multiple plasmids, including IncF, IncI1, and IncX types, alongside chromosomal mutations in gyrA, parC, and pmrB [5]. Such strains exhibit resistance to all antimicrobial classes approved for poultry use.

5.2.3 ST131 and High-Risk Clones

Escherichia coli ST131, a globally disseminated human ExPEC lineage, has been identified in poultry populations. Comparative analysis of clinical and non-clinical E. coli from chickens reveals overlapping AMR patterns of One Health significance, with ST131 isolates harboring blaCTX-M-15, blaCTX-M-27, and fluoroquinolone resistance mutations [6]. Pet birds have also been documented as potential reservoirs of antimicrobial-resistant bacteria in digestive and respiratory infections, suggesting bidirectional transmission pathways [7].

5.3 Regional Epidemiology

Prevalence of antimicrobial-resistant bacterial pathogens among livestock in subtropical environments shows elevated resistance rates attributable to climatic factors influencing bacterial persistence and horizontal gene transfer [8]. Integrated surveillance across poultry, swine, and bovine sectors is essential for tracking clonal spread.

6. Control Strategies

6.1 Biosecurity and Management

6.1.1 Structural Biosecurity

• Perimeter fencing with controlled access points
• Dedicated footwear and clothing per house
• Rodent and wild bird exclusion programs
• Vehicle disinfection stations with validated contact times

6.1.2 Operational Biosecurity

• All-in/all-out production with minimum 14-day downtime
• Litter management: moisture control <25%, ammonia <25 ppm
• Water sanitation: oxidative disinfectants maintaining ORP >650 mV
• Feed hygiene: heat treatment or organic acid supplementation

6.1.3 Stress Mitigation

Environmental stressors (heat, cold, ammonia, overcrowding) impair mucociliary clearance and macrophage function. Ventilation management targeting CO2 <3000 ppm and dust <3.4 mg/m3 reduces respiratory compromise.

6.2 Vaccination Strategies

6.2.1 Commercial Live Attenuated Vaccines

AraC-negative, temperature-sensitive mutants administered via coarse spray or drinking water at 1 day of age provide mucosal IgA and systemic IgY responses. Protection is serogroup-specific, necessitating multivalent formulations covering prevalent O-serogroups.

6.2.2 Inactivated Bacterins

Oil-emulsion inactivated vaccines administered subcutaneously or intramuscularly at 10-12 weeks induce high-titer IgY transferred to progeny via yolk. Efficacy correlates with antigenic match between vaccine strains and field isolates.

6.2.3 Autogenous Vaccines

Custom-manufactured from farm-specific isolates, autogenous vaccines address antigenic diversity unmet by commercial products. Strain selection utilizes WGS data to ensure representation of circulating virulence and resistance profiles. Regulatory frameworks require veterinary prescription and licensed manufacturing facilities.

6.2.4 Subunit and Novel Vaccine Platforms

Comparative evaluation of outer membrane protein (OMP) and whole-cell antigen vaccines demonstrates superior cross-protection of OMP preparations against heterologous APEC challenge [9]. Multi-epitope vaccine design informed by machine learning identifies conserved protective epitopes across APEC lineages [10]. An IgM monoclonal antibody targeting diguanylate cyclase DgcE potentiates gentamicin activity against APEC through modulation of cyclic-di-GMP signaling, representing a novel immunotherapeutic adjunct [11]. Albumin-based nanoparticle vaccines incorporating target antigens show enhanced immunogenicity and lymph node targeting [12].

6.2.5 Phytogenic and Alternative Approaches

Essential oils such as Cymbopogon flexuosus demonstrate antibacterial and antibiofilm activity against multidrug-resistant APEC isolates, with molecular docking studies identifying binding to virulence regulators [13]. Myrmecodia sp. extract modulates organ function biomarkers, lipid metabolism, and meat lipid profile in APEC-infected broilers, suggesting nutraceutical applications within a One Health framework [14].

6.3 Antimicrobial Stewardship

6.3.1 Treatment Guidelines

• First-line: Guided by susceptibility testing; avoid fluoroquinolones and third-generation cephalosporins for empiric therapy
• Duration: Minimum 5 days; extend based on clinical response
• Route: Parenteral for septicemia; oral for localized infections
• Withdrawal periods: Strict adherence to regulatory mandates

6.3.2 Alternatives to Antimicrobials

• Competitive exclusion products: Defined microbiota cultures administered at hatch
• Organic acids: Formic, propionic, and butyric acid blends in feed/water
• Bacteriophages: Lytic phage cocktails targeting prevalent APEC serogroups
• Antimicrobial peptides: Synthetic defensins and cathelicidins under investigation

6.4 Integrated Control Programs

Successful programs combine:

1. Surveillance: Quarterly AMR monitoring via standardized broth microdilution
2. Vaccination: Prime-boost strategies (live prime, inactivated boost)
3. Biosecurity: Audited compliance with corrective action tracking
4. Diagnostics: Rapid PCR-based pathogen detection for targeted intervention
5. Data Integration: Farm management software linking production parameters, diagnostic results, and treatment records

7. One Health Implications

APEC serves as a reservoir for resistance genes transferable to human pathogens via food chain, environmental contamination, and direct contact. The genetic overlap between avian and human ExPEC, particularly within ST131 and other high-risk clones, underscores the necessity for coordinated surveillance. Carbapenemase detection in livestock-associated E. coli [1] mandates enhanced biosecurity at the human-animal interface. Computational approaches including biological foundation models for predicting host tropism and pathogenicity may improve risk assessment of emerging clones [16].

8. Future Directions

• CRISPR-based diagnostics: Cas12a/Cas13a systems for point-of-need AMR gene detection
• Pan-genome reverse vaccinology: In silico identification of conserved protective antigens
• Microbiome modulation: Precision prebiotics/probiotics enhancing colonization resistance
• Phage therapy cocktails: Engineered phages with expanded host range and anti-biofilm activity
• Host genetic selection: Breeding for enhanced innate immune responses to APEC

9. Conclusions

Avian colibacillosis remains a multifactorial challenge requiring integrated diagnostic, therapeutic, and preventive approaches. Molecular diagnostics enable precise pathogen characterization, informing both treatment decisions and autogenous vaccine formulation. The escalating AMR crisis, exemplified by carbapenemase-producing and XDR APEC lineages, necessitates antimicrobial stewardship and alternative control strategies. Sustainable poultry production depends on continued investment in surveillance, vaccine innovation, and One Health collaboration.

References

[1] Veldman KT, van Essen-Zandbergen A, Geurts Y et al. Description of OXA-244 carbapenemase-producing Escherichia coli in farm animals in The Netherlands, 2024. J Antimicrob Chemother. 2026. https://pubmed.ncbi.nlm.nih.gov/42136198/

[2] Runcharoon K, Ienes-Lima J, Logue CM. Complete genomes of 21 avian pathogenic Escherichia coli isolated from colibacillosis cases in Georgia poultry. Microbiol Resour Announc. 2026. https://pubmed.ncbi.nlm.nih.gov/42132918/

[3] Jing Y, Shen X, Yin D et al. The ecnAB toxin-antitoxin system modulates avian pathogenic Escherichia coli virulence through regulating the capsular sialic acid biosynthesis pathway. Vet Microbiol. 2026. https://pubmed.ncbi.nlm.nih.gov/42160786/

[4] Xuan H, Wang S, Ren X et al. Rapid visual detection of Mycoplasma gallisepticum by combining recombinase-aided amplification with lateral-flow dipstick assay. Poult Sci. 2026. https://pubmed.ncbi.nlm.nih.gov/42127851/

[5] Ni W, Chen L, Chen H et al. Genomic and Pathogenic Characterization of an Extensively Drug-Resistant Avian Pathogenic Escherichia coli Strain. Transbound Emerg Dis. 2026. https://pubmed.ncbi.nlm.nih.gov/42147456/

[6] de Souza Campos MR, Dias TS, Gonçalves VD et al. Clinical and non-clinical Escherichia coli from chickens reveal antimicrobial resistance patterns of one health concern. Comp Immunol Microbiol Infect Dis. 2026. https://pubmed.ncbi.nlm.nih.gov/42119341/

[7] Crăciun S, Turcu MC, Novac CŞ et al. Pet Birds as Potential Reservoirs of Antimicrobial-Resistant Bacteria in Digestive and Respiratory Infections. Antibiotics (Basel). 2026. https://pubmed.ncbi.nlm.nih.gov/42192709/

[8] Kanwal B, Asif E, Kalhoro NH et al. Prevalence of Antimicrobial-Resistant Bacterial Pathogens Among Livestock in Subtropical Environments. Antibiotics (Basel). 2026. https://pubmed.ncbi.nlm.nih.gov/42192683/

[9] Wani BM, Kamil SA, Shah SA et al. Comparative evaluation of outer membrane protein and whole cell antigen vaccine against avian pathogen Escherichia coli infection in broiler chicken. Iran J Microbiol. 2026. https://pubmed.ncbi.nlm.nih.gov/42112298/

[10] Waseem M, Kamran Z, Ali A. Advancing poultry health: A meta-analysis of epitope-based and peptide-based vaccines against Avian Pathogenic E. coli with machine learning insights. PLoS One. 2026. https://pubmed.ncbi.nlm.nih.gov/42201941/

[11] Fangfang L, Lianhua N, Haiyang W et al. An IgM monoclonal antibody targeting diguanylate cyclase DgcE potentiates gentamicin activity against avian pathogenic Escherichia coli through modulation of c-di-GMP signaling. BMC Vet Res. 2026. https://pubmed.ncbi.nlm.nih.gov/42226053/

[12] Bagheri A, Ghobadi S, Mostafaie A et al. A novel albumin-based nanoparticle vaccine including the globular knob domain of the egg drop syndrome virus fiber protein for egg drop syndrome: Immunogenicity and preliminary structural analyses. Int Immunopharmacol. 2026. https://pubmed.ncbi.nlm.nih.gov/42143501/

[13] Dhaouadi S, Khamessi O, Dassi RB et al. Leveraging the antibacterial and antibiofilm activities of Cymbopogon flexuosus essential oil against multidrug-resistant bacteria recovered from avian colibacillosis and bovine mastitis: in vitro and molecular docking insights. Vet Res Commun. 2026. https://pubmed.ncbi.nlm.nih.gov/42240774/

[14] Lisnanti EF, Lokapirnasari WP, Arif MAA et al. Comparative effects of Myrmecodia sp. extract and infusion on organ function biomarkers, lipid metabolism, and meat lipid profile in avian pathogenic Escherichia coli-infected broiler chickens: Implications for sustainable poultry production within a One Health framework. Vet World. 2026. https://pubmed.ncbi.nlm.nih.gov/42245456/

[15] Zahra B, Behzad H, Morteza T et al. Multi-epitope HA Vaccine Confers Cross-protective Immunity to H5N8 and H9N2. Arch Razi Inst. 2025. https://pubmed.ncbi.nlm.nih.gov/42226989/